Premium
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment—Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al
Author(s) -
Bubb Michael R.
Publication year - 2019
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.40914
Subject(s) - febuxostat , gout , allopurinol , medicine , xanthine oxidase , xanthine oxidase inhibitor , veterans affairs , physical therapy , library science , gerontology , family medicine , hyperuricemia , uric acid , computer science , chemistry , biochemistry , enzyme